People | January 21, 2022
DefiniGen promotes Dr Chris Kirton to CEO
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Biocon has reported consolidated financial results for the period ended December 31, 2021
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
First launches expected in H1 2022
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
Subscribe To Our Newsletter & Stay Updated
